In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Once a rarely used subset of medical treatments, protein therapeutics have increased
dramatically in number and frequency of use since the introduction of the first recombinant …

PURPOSE Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-
cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML). The aim of …

The transfer of polymer–protein conjugates into routine clinical use, and the clinical
development of polymer–anticancer-drug conjugates, both as single agents and as …

Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …

Background We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a
pegylated version of filgrastim) per cycle of chemotherapy, compared with daily …

Interdisciplinary research at the interface of polymer chemistry and the biomedical sciences
has produced the first polymer-based nanomedicines for the diagnosis and treatment of …

Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal
transformation of hematopoietic precursors through the acquisition of chromosomal …

Following its highly successful and well-respected first edition, this thoroughly revised
edition offers much more! Edited and authored by leading authorities in hematology, this …

Myeloid growth factors (MGFs) are given as supportive care to patients receiving
myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from …